Observational studyBMC cardiovascular disorders2026
Multimodal non-invasive ultrasound for predicting severe coronary artery stenosis in right coronary dominant patients.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo assess the predictive value of multimodal non-invasive ultrasound in detecting severe coronary artery stenosis (CAS) in patients with right coronary artery dominance.
methodsThis prospective observational study enrolled patients undergoing coronary angiography and non-invasive echocardiography at the Department of Cardiology, Luzhou People's Hospital, between December 2021 and August 2023. Severe CAS (SCAS) was defined as CAS ≥ 75% based on angiographic results. Patients were categorized into the SCAS group and the NSCAS group (non-severe CAS).
resultsA total of 121 patients were included, with 98 in the NSCAS group and 23 in the SCAS group. Compared to the NSCAS group, the SCAS group showed a lower left ventricular ejection fraction (LVEF) (49.3 ± 9.8% vs. 58.9 ± 5.2%, p = 0.028), a higher left ventricular end-systolic diameter(LVsd) (35.2 ± 7.7 mm vs. 29.8 ± 5.0 mm, p = 0.020), and a higher end-systolic volume༈ESV༉ (54.0 ± 23.0 ml vs. 35.7 ± 21.8 ml, p = 0.041). According to the receiver operating characteristic curve analysis, the optimal cutoff values for predicting SCAS are as follows: motion score, 1.5; ESV, 47.5 ml; LVsd, 30.5 mm; LVEF, 53.5%; mitral annular systolic velocity༈Smv༉, 8.5 cm/s; and global longitudinal peak strain༈GLPS༉, -16.5% (all p < 0.05). Multivariate logistic regression showed that LVEF was associated with SCAS (OR = 1.600, 95% CI:1.037-2.468, P = 0.034).
conclusionsOur findings suggest that LVEF may play a role in predicting SCAS, validating non-invasive ultrasound as an effective early diagnostic tool for patients with right coronary artery dominance.
trial registrationNot applicable.
Indexed as
Identifiers
42919135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.